| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | piperlongumine | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.2 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.2 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |